Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

AFL · Q4 2025 Earnings

Aflac

Reported February 4, 2026

30-second summary

30-second take: Aflac closed 2025 with Q4 revenue of $4.87B (-9.9% YoY, distorted by prior-year investment gains comparisons) and adjusted EPS of $1.57; full-year adjusted EPS of $7.49 on $17.16B revenue. The substantive news is the FY2026 guidance reset: Japan pre-tax margin guided to 33–36% (vs. prior FY2025 framework of 35–38%), Japan benefit ratio guided up to 60–63% (vs. 58–60%), and US pre-tax margin pulled to a full 17–20% range (vs. the "upper end" framing committed last quarter). Management is telling the market both segments operate at lower margins next year — and that Japan underlying earned premiums will still decline 1–2% in 2026, meaning the inflection thesis from Q2/Q3 is now explicitly pushed past the 2026 window.

Headline numbers

EPS

Q4 FY2025

$1.57

Revenue

Q4 FY2025

$4.87B

-9.9% YoY

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$4.87B	-9.9%	$4.74B	+2.7%
EPS	$1.57	—	$2.49	-36.9%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Aflac Japan underlying earned premiums growth	FY 2026	decline 1% to 2%	—
Aflac Japan expense ratio	FY 2026	20% to 23%	—
Aflac Japan benefit ratio	FY 2026	60% to 63%	—
Aflac Japan pre-tax profit margin	FY 2026	33% to 36%	—
Aflac U.S. net earned premium growth	FY 2026	lower end of 3% to 6%	—
Aflac U.S. benefit ratio	FY 2026	48% to 52%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Aflac Japan benefit ratio	FY 2025	58% to 60%	60% to 63%	+2-3pts wider on the upside (60-63% vs 58-60%)	Lowered
Aflac Japan expense ratio	FY 2025	lower end of 20% to 23% range	20% to 23%	Expanded from lower end (≈20%) to full range (20-23%)	Raised
Aflac Japan pre-tax profit margin	FY 2025	35% to 38%	33% to 36%	-2pts on both low and high end	Lowered
Aflac U.S. benefit ratio	FY 2025	lower end of 48% to 52% range	48% to 52%	Expanded from lower end (≈48%) to full range (48-52%); ~200bps upside on midpoint	Raised
Aflac U.S. expense ratio	FY 2025	mid to upper end of 36% to 39% range	36% to 39%	Shifted from mid-to-upper (≈37.5%) to full range (36-39%); ~75bps downside on midpoint	Lowered
Aflac U.S. pre-tax profit margin	FY 2025	upper end of 17% to 20% range	17% to 20%	Shifted from upper end (≈19.5%) to full range (17-20%); ~150bps downside on midpoint	Lowered

Reaffirmed unchanged this quarter: Aflac U.S. net earned premium growth (lower end of 3% to 6% range)

Segment performance

Q4 FY2025

Segment	Q4 FY2025	YoY
Aflac Japan	$0.712B	-4.7%
Aflac U.S.	$0.3B	-9.1%

Capital & returns

Q4 FY2025

Segment	Q4 FY2025
Adjusted ROE (excluding FX remeasurement)	14.5%
Book Value Per Share	$56.85
Adjusted Book Value Per Share	$54.06
Adjusted Debt to Adjusted Capitalization	24.7%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Aflac U.S. Premium Persistency (12-month rolling)	79.2%
Aflac U.S. Annualized Premiums In Force	$6.694 billion
Aflac U.S. New Annualized Premium Sales	$551 million
Investment Portfolio Book Yield (Aflac U.S.)	5.47%

Management tone

Narrative arc: Q2 stabilization candidate → Q3 multi-product offensive → Q4 margin reset with inflection pushed out.

Two quarters ago Japan was framed as an inflection candidate where Yoshizumi underwrote 2025 sales > 2024; last quarter as a three-product offensive (Miraito, Sumitasa, December medical launch) with formal segment ratios giving the market a scorecard; this quarter management is explicitly resetting that scorecard lower and pushing the premium inflection past 2026. From the call: "once that turns positive is eventually when we are going to have net earned premium growth in Japan…even going into 2026, we still expect that lapses will be greater than total sales." The Q2/Q3 inflection thesis is not abandoned — it is simply now a 2027+ event. This is a material elongation of the recovery timeline.

The Japan benefit-ratio shift is being framed as repricing and assumption update, not deterioration — but the framing itself is what changed. Last quarter the 58–60% band was the structural guardrail; this quarter Max walks through three drivers: a 130bps lower net premium ratio from the Q3 actuarial assumption update, elevated lapse-and-reissue activity tied to new product introductions, and runoff of the older "waze" first-sector savings block. The mechanics are technical and defensible, but the net effect is that the ratio framework introduced just one quarter ago is already being reset in management's first revision opportunity.

US growth posture has shifted from "exceeding our trajectory" to "level expectations after enormous 2025." Last quarter Virgil characterized US sales as running ahead of plan with 4Q LAD momentum confirmed in advance. This quarter Dan said: "we had enormous sales in 2025, and we would expect sales to be more level." The retrenchment to flat-to-low growth framing within nine months of the "exceeding trajectory" comment is the second downshift management has communicated in tone this quarter alongside Japan.

The US mix-shift thesis has hardened into the visible operating story. From Virgil: "if you look at isolated just on group policies…the overall growth would have been 14%" vs. 3.1% total US sales growth. This validates the structural narrative from Q3 that the portfolio is genuinely reshaping toward group benefits — but it also means the traditional voluntary block is a deeper drag than the headline implies, and the US benefit ratio drifting up to the full 48–52% range is the structural cost of that mix shift.

The ESR/USP capital framing has weakened in a way that wasn't on the table last quarter. Max: "As yen interest rates go higher, the impact from the USP will decline a little bit." The USP benefit to regulatory ESR has fallen from ~30 points to ~18 points. This doesn't impair capital deployment — ESR 253% (USP-adjusted), RBC 575%, $4.1B unencumbered, $3.5B buybacks signaled — but it does mean a previously stable capital tailwind is now a sensitivity.

Recurring themes management leaned on this quarter:

Japan sales acceleration from new products (Morito +35.6%, On Shin Pallet launch) but normalization expected in 2026US group benefits (life, disability, dental) becoming material growth driver with 14% isolated growth vs. traditional voluntary persistence dragJapan earned premium inflection delayed; persistency strength paradoxically slowing growth as lapsation > sales still in 2026Benefit ratio normalization: Japan declining 60-63% due to assumption updates and product mix; US rising 48-52% due to benefit increases and group product mix shiftCapital and liquidity fortress with $4.1B unencumbered, ESR 253% (USP-adjusted), RBC 575%, enabling $3.5B share buybacks and dividend growthAI investment focus on claims automation (60%+ of traditional) and enrollment efficiency rather than agent replacement

Risks management surfaced:

Yen interest rate sensitivity on first-sector savings block; higher rates could drive surrenders despite stable experience to dateJapan earned premium growth inflection delayed; negative 1-2% expected 2026, positive inflection timing uncertainUS traditional voluntary benefits flat-to-negative for multiple years; legacy drag offsetting group momentumESR regulatory capital metric now showing reduced USP benefit (18 pts vs 30 pts) from yen interest rate movesCommercial real estate and middle market loan portfolio credit risk (no Q4 CRE charge-offs but $22M middle market loan charge-offs)

Answers to last quarter's watch list

Q4 Japan medical insurance launch traction — The press release does not disclose first-90-day annualized new premium for the December medical launch in a way that isolates the product. Management's broader framing of 2026 sales as "more level" implies the multi-product strategy is not creating step-function acceleration into 2026, but specific medical-launch traction wasn't called out on the print. Status: Continue monitoring

Japan benefit ratio landing inside 58–60% — Resolved with the guidance revision: FY2025 Japan benefit ratio guidance was lifted to 60–63%, explicitly outside the prior 58–60% band. Management attributes the move to assumption updates and product mix rather than deterioration, but the disclosure framework's credibility — set just one quarter ago — has taken a hit on its first test. Status: Resolved negatively

US pre-tax margin at upper end of 17–20% — Resolved unfavorably: the "upper end" qualifier was removed for FY2025 and FY2026 is also guided to the full 17–20% range. This is the exact "quietly slips to within range" outcome flagged in the Q3 watch list. Status: Resolved negatively

Sustainability of US LAD/group momentum — Group policies grew 14% in isolation per Virgil, well above the 3.1% blended US sales growth, confirming the group/LAD momentum from Q3 persists. The US pre-tax margin reset, however, suggests this momentum is not enough to offset the mix-shift cost into benefit ratios. Status: Resolved positively on volume, negatively on margin

Japan FSA earnings normalization vs. ¥200B core run-rate — The press release doesn't provide a clean FSA earnings split for Q4, but management's tone language flags the USP-to-ESR benefit declining from 30pts to 18pts on yen rate moves — confirming the FX/rate sensitivity Max called out last quarter is now visible in disclosed metrics. Status: Continue monitoring

Buyback pacing post-record quarter — Management signaled $3.5B share buybacks (forward), implying a roughly $875M quarterly run-rate — below the Q3 record but well above historical pace. The record was somewhat opportunistic, but the new baseline is materially elevated. Status: Resolved positively

What to watch into next quarter

Japan benefit ratio actual landing inside 60–63%: the new band is the second framework in two quarters. A miss to the upside on the Q1 print would suggest the assumption update was insufficient and trigger a third revision — a credibility problem for the ratio guidance regime.

Japan underlying earned premium trend vs. -1% to -2% guide: management has now pushed the inflection past 2026. Watch whether the -1.2% Q4 underlying trend deteriorates further or compresses — the latter would set up a 2027 inflection thesis.

US net earned premium growth crossing into mid-3% range: management has held "lower end of 3–6%" through three quarters now. An acceleration above ~3.5% would validate the group/LAD mix shift; staying anchored at 3.0% suggests legacy voluntary drag is deepening.

US group/LAD isolated growth holding double-digit: Virgil's 14% group-isolated number is the cleanest momentum signal. Watch whether the next disclosure holds at or above that level.

Buyback pacing vs. ~$875M quarterly run-rate implied by $3.5B annual signal: a Q1 print at or above that level confirms programmatic intent; a step-down to ~$700M reverts the Q3 record back toward opportunism.

USP-to-ESR benefit trajectory: 30pts → 18pts is the new data point. Any further compression on yen rate moves would materially change the capital deployment math management has been pacing into.

Sources

Aflac Q4 2025 Financial Supplement (SEC): https://www.sec.gov/Archives/edgar/data/4977/000162828026005458/afl123125-fabdocument.htm
Aflac Incorporated Q4 2025 Earnings Conference Call transcript (Dan Amos, Max Brodén, Virgil Miller, Yoshizumi), February 4, 2026.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.